These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

208 related items for PubMed ID: 30472602

  • 21. N-Arylsulfonylsubstituted-1H indole derivatives as small molecule dual inhibitors of signal transducer and activator of transcription 3 (STAT3) and tubulin.
    Zhou Q, Zhu J, Chen J, Ji P, Qiao C.
    Bioorg Med Chem; 2018 Jan 01; 26(1):96-106. PubMed ID: 29174507
    [Abstract] [Full Text] [Related]

  • 22. Discovery, synthesis, and evaluation of small-molecule signal transducer and activator of transcription 3 inhibitors.
    Shi ZB, Zhao D, Huang YY, Du Y, Cao XR, Gong ZN, Zhao R, Li JX.
    Chem Pharm Bull (Tokyo); 2012 Jan 01; 60(12):1574-80. PubMed ID: 23207637
    [Abstract] [Full Text] [Related]

  • 23. Thermal Proteome Profiling in Zebrafish Reveals Effects of Napabucasin on Retinoic Acid Metabolism.
    Leijten NM, Bakker P, Spaink HP, den Hertog J, Lemeer S.
    Mol Cell Proteomics; 2021 Jan 01; 20():100033. PubMed ID: 33594990
    [Abstract] [Full Text] [Related]

  • 24. Bifunctional Naphthoquinone Aromatic Amide-Oxime Derivatives Exert Combined Immunotherapeutic and Antitumor Effects through Simultaneous Targeting of Indoleamine-2,3-dioxygenase and Signal Transducer and Activator of Transcription 3.
    Huang R, Jing X, Huang X, Pan Y, Fang Y, Liang G, Liao Z, Wang H, Chen Z, Zhang Y.
    J Med Chem; 2020 Feb 27; 63(4):1544-1563. PubMed ID: 31999451
    [Abstract] [Full Text] [Related]

  • 25. Discovery of P3971 an orally efficacious novel anticancer agent targeting HIF-1α and STAT3 pathways.
    Godse P, Kumar P, Yewalkar N, Deore V, Lohar M, Mundada R, Padgaonkar A, Manohar S, Joshi A, Bhatia D, Desai N, Damre A, Bhonde M, Joshi K, Sharma R, Kumar S.
    Anticancer Agents Med Chem; 2013 Nov 27; 13(9):1460-6. PubMed ID: 24102269
    [Abstract] [Full Text] [Related]

  • 26. Evaluation of Tumor Cell-Tumor Microenvironment Component Interactions as Potential Predictors of Patient Response to Napabucasin.
    Chang AY, Hsu E, Patel J, Li Y, Zhang M, Iguchi H, Rogoff HA.
    Mol Cancer Res; 2019 Jul 27; 17(7):1429-1434. PubMed ID: 31043490
    [Abstract] [Full Text] [Related]

  • 27. Napabucasin versus placebo in refractory advanced colorectal cancer: a randomised phase 3 trial.
    Jonker DJ, Nott L, Yoshino T, Gill S, Shapiro J, Ohtsu A, Zalcberg J, Vickers MM, Wei AC, Gao Y, Tebbutt NC, Markman B, Price T, Esaki T, Koski S, Hitron M, Li W, Li Y, Magoski NM, Li CJ, Simes J, Tu D, O'Callaghan CJ.
    Lancet Gastroenterol Hepatol; 2018 Apr 27; 3(4):263-270. PubMed ID: 29397354
    [Abstract] [Full Text] [Related]

  • 28. STAT3 inhibitor Napabucasin abrogates MDSC immunosuppressive capacity and prolongs survival of melanoma-bearing mice.
    Bitsch R, Kurzay A, Özbay Kurt F, De La Torre C, Lasser S, Lepper A, Siebenmorgen A, Müller V, Altevogt P, Utikal J, Umansky V.
    J Immunother Cancer; 2022 Mar 27; 10(3):. PubMed ID: 35301236
    [Abstract] [Full Text] [Related]

  • 29. Discovery of potent anticancer agent HJC0416, an orally bioavailable small molecule inhibitor of signal transducer and activator of transcription 3 (STAT3).
    Chen H, Yang Z, Ding C, Xiong A, Wild C, Wang L, Ye N, Cai G, Flores RM, Ding Y, Shen Q, Zhou J.
    Eur J Med Chem; 2014 Jul 23; 82():195-203. PubMed ID: 24904966
    [Abstract] [Full Text] [Related]

  • 30. Discovery of monocarbonyl curcumin-BTP hybrids as STAT3 inhibitors for drug-sensitive and drug-resistant breast cancer therapy.
    Zhang W, Guo J, Li S, Ma T, Xu D, Han C, Liu F, Yu W, Kong L.
    Sci Rep; 2017 Apr 11; 7():46352. PubMed ID: 28397855
    [Abstract] [Full Text] [Related]

  • 31. Bioactivation of Napabucasin Triggers Reactive Oxygen Species-Mediated Cancer Cell Death.
    Froeling FEM, Swamynathan MM, Deschênes A, Chio IIC, Brosnan E, Yao MA, Alagesan P, Lucito M, Li J, Chang AY, Trotman LC, Belleau P, Park Y, Rogoff HA, Watson JD, Tuveson DA.
    Clin Cancer Res; 2019 Dec 01; 25(23):7162-7174. PubMed ID: 31527169
    [Abstract] [Full Text] [Related]

  • 32. Identification of novel STAT3 inhibitors bearing 2-acetyl-7-phenylamino benzofuran scaffold for antitumour study.
    Wang F, Feng KR, Zhao JY, Zhang JW, Shi XW, Zhou J, Gao D, Lin GQ, Tian P.
    Bioorg Med Chem; 2020 Dec 15; 28(24):115822. PubMed ID: 33126089
    [Abstract] [Full Text] [Related]

  • 33. Discovery of oral-available resveratrol-caffeic acid based hybrids inhibiting acetylated and phosphorylated STAT3 protein.
    Li S, Zhang W, Yang Y, Ma T, Guo J, Wang S, Yu W, Kong L.
    Eur J Med Chem; 2016 Nov 29; 124():1006-1018. PubMed ID: 27783972
    [Abstract] [Full Text] [Related]

  • 34. Discovery of an Orally Selective Inhibitor of Signal Transducer and Activator of Transcription 3 Using Advanced Multiple Ligand Simultaneous Docking.
    Yu W, Li C, Zhang W, Xia Y, Li S, Lin JY, Yu K, Liu M, Yang L, Luo J, Chen Y, Sun H, Kong L.
    J Med Chem; 2017 Apr 13; 60(7):2718-2731. PubMed ID: 28245116
    [Abstract] [Full Text] [Related]

  • 35. Design, synthesis, and biological evaluation of novel napabucasin-melatonin hybrids as potent STAT3 inhibitors.
    Zhang C, Yang L, Yang X, Gao Q, Qu Y, Wu L.
    Bioorg Chem; 2023 Jul 13; 136():106541. PubMed ID: 37062104
    [Abstract] [Full Text] [Related]

  • 36. Napabucasin (BBI 608), a potent chemoradiosensitizer in rectal cancer.
    Nagaraju GP, Farran B, Farren M, Chalikonda G, Wu C, Lesinski GB, El-Rayes BF.
    Cancer; 2020 Jul 15; 126(14):3360-3371. PubMed ID: 32383803
    [Abstract] [Full Text] [Related]

  • 37. Synthesis and Biological Evaluation of Novel 2-Amino-1,4-Naphthoquinone Amide-Oxime Derivatives as Potent IDO1/STAT3 Dual Inhibitors with Prospective Antitumor Effects.
    Huang RZ, Liang QL, Jing XT, Wang K, Zhang HY, Wang HS, Ma XL, Wei JH, Zhang Y.
    Molecules; 2023 Aug 19; 28(16):. PubMed ID: 37630387
    [Abstract] [Full Text] [Related]

  • 38. Synthesis and structure-activity relationship studies of naphthoquinones as STAT3 inhibitors.
    Yamashita M, Nakamori Y, Tsukamoto A, Furuno N, Iida A.
    Bioorg Med Chem; 2023 Jul 15; 90():117331. PubMed ID: 37343498
    [Abstract] [Full Text] [Related]

  • 39. Discovery of novel STAT3 small molecule inhibitors via in silico site-directed fragment-based drug design.
    Yu W, Xiao H, Lin J, Li C.
    J Med Chem; 2013 Jun 13; 56(11):4402-12. PubMed ID: 23651330
    [Abstract] [Full Text] [Related]

  • 40. Novel aminotetrazole derivatives as selective STAT3 non-peptide inhibitors.
    Pallandre JR, Borg C, Rognan D, Boibessot T, Luzet V, Yesylevskyy S, Ramseyer C, Pudlo M.
    Eur J Med Chem; 2015 Oct 20; 103():163-74. PubMed ID: 26352675
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 11.